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Abstract
Background: Fibromyalgia is a condition characterized by chronic widespread muscle pain and fatigue and associated
with significant impairment in perceived function and reduced physical performance. The purpose of this study was to
determine the degree to which pain and fatigue are associated with perceived function and physical performance in
women with fibromyalgia.
Methods: Hierarchical linear regression determined the contribution of pain and fatigue (Numeric Rating Scale (NRS)
for resting, movement and combined) to perceived function (Fibromyalgia Impact Questionnaire Revised - Function
Subscale, FIQR-Function), Multidimensional Assessment of Fatigue - Activities of Daily Living (MAF-ADL) and SF-36
Physical Function Subscale (SF-36-PF) and physical performance (6-Minute Walk Test, 6MWT and Five Time Sit To Stand,
5TSTS) while controlling for age, body mass index, pain catastrophizing, fear of movement, anxiety, and depression in
women with fibromyalgia (N = 94).
Results: For perceived function, movement pain and movement fatigue together better predicted FIQR-function
(adjusted R2 = 0.42, p ≤ 0.001); MAF-ADL (adjusted R2 = 0.41, p ≤ 0.001); and SF-36-PF function (adjusted R2 = 0.34,
p ≤ 0.001). For physical performance measures, movement pain and fatigue together predicted 6MWT distance
(adjusted R2 = 0.42, p ≤ 0.001) and movement fatigue alone predicted performance time on the 5TSTS (adjusted
R2 = 0.20, p ≤ 0.001).
Conclusions: Pain and fatigue are significantly associated with and explain more than one-third of the variance
in perceived function and physical performance in women with fibromyalgia.
Trial registration: NIH Clinicaltrials.gov Registration: NCT01888640. Registered 13 June 2013.
Background
Fibromyalgia is a condition characterized by chronic wide-
spread muscle pain, affecting 4–10 % of the US popula-
tion, the majority of which are women [1–3]. While pain
is the defining characteristic for diagnosing fibromyalgia,
fatigue is also a common complaint for individuals with
fibromyalgia. For example, Bennett et al. [4] found pain
and fatigue emerged as the top two of six distinct clinical
features of fibromyalgia in a sample of 788 people with
fibromyalgia; 54 % perceived pain as their primary symp-
tom and 28 % perceived fatigue as their main complaint.
That study indicated while pain and fatigue commonly
co-occur, they are clearly differentiated in people with
fibromyalgia. One of the most challenging aspects of
fibromyalgia is the variable nature of pain among indi-
viduals with fibromyalgia [5]. Pain for individuals with
fibromyalgia may be associated with morning stiffness as
well as pain increases throughout the day [6]. Average
daily pain ratings may vary in individuals with
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fibromyalgia with increased pain in the morning and
evening [7]. Henriksson found that many people with
fibromyalgia describe activities that aggravate the symp-
toms of fibromyalgia include carrying and holding objects
and these activities are perceived as strenuous [8]. Pain in
individuals with fibromyalgia has been associated with
greater disease severity, reduced function and symptoms
of fibromyalgia [9, 10]. Thus, pain is a significant symptom
that may contribute to participation in physical function.
The perception of fatigue is a significant symptom that,
in addition to pain, may contribute to reduced participa-
tion in daily physical activities. Although fatigue is not
part of the American College of Rheumatology (ACR)
clinical definition published in 1990, it is taken into con-
sideration as part of the newer criteria published in 2010
[11, 12]. Fatigue is a major symptom that impacts function
and is reported in nearly 100 % of the population [11, 13]
People with fibromyalgia typically describe their physical
fatigue as an overall feeling of tiredness or exhaustion [2],
as a failure to initiate or sustain physical activities [14], or
having to take things slower in order to accomplish tasks
[15]. Individuals with fibromyalgia frequently report diffi-
culty with daily functional tasks (e.g., pouring a cup of cof-
fee, folding laundry, drying hair or getting dressed), [2, 15]
strenuous physical activities, and cognitive tasks such as
paying bills [15].
Function is significantly impaired in people with fibro-
myalgia with poor perceived function observed on several
self-report measures [4, 16–21]. Physical performance on
clinical tests, such as the 6-Minute Walk Test (6MWT) or
Five Time Sit To Stand (5TSTS) test, is also significantly re-
duced in this population when compared to healthy con-
trols [22–24] Perceived function does not directly assess
physical performance, and self-report and physical perform-
ance are not strongly correlated [25, 26]. Clinically, people
with fibromyalgia report that both pain and fatigue are
major barriers to their ability to participate in regular activ-
ities [2, 15]. Pain and fatigue during functional activities,
particularly movement pain and movement fatigue, may be
greater barriers to participation in these activities and are
significantly increased in people with fibromyalgia during
fatiguing exercise tasks [25, 27, 28]. However, the degree to
which pain and fatigue diminish perceived function and
physical performance has not been well investigated.
Accordingly, the primary purpose of this study was to
determine the degree to which self-reported pain and fa-
tigue intensities are associated with perceived function
and physical performance in women with fibromyalgia.
We hypothesized that higher levels of pain and fatigue
would be associated with reductions in perceived func-
tion and physical performance, with pain and fatigue
intensity each contributing unique information to the
model. A secondary purpose was to investigate whether
pain and fatigue assessed during rest, movement or the
change between rest and movement would best predict
perceived function and physical performance.
Methods
This study is a supplementary analysis using baseline data
from a clinical trial, Fibromyalgia Activity Study with TENS
(FAST) [29] before randomization to a Transcutaneous
Electrical Nerve Stimulation (TENS) treatment. Following
completion of written consent, demographic information
was gathered for the participants with respect to age, sex,
ethnicity, marital status, education, income, body mass
index (BMI) and length of diagnosis of fibromyalgia
(Table 1). Internal consistency was calculated for measures
of pain, fatigue, physical performance, perceived function
and control variables (Tables 1 and 2). Additional details
Table 1 Subject characteristics at baseline visit (N = 94 women)
Variable Mean ± SD or
N (%)
Range Cronbach's α
Age (years) 49.2 ± 11.0 20 to 67
BMI 33.8 ± 7.3 19.1 to 70.2
Caucasian 88 (93.6 %) -
Marital status:
Married/cohabitating 46 (48.9 %) -
Single/widowed/divorced 46 (48.9 %) -
No answer 2 (2.1 %) -
Education:
High school or less 24 (25.5 %) -
Some college or more 66 (70.2 %) -
No answer 4 (4.3 %) -
Annual income:
< $60,000 60 (63.8 %) -
≥ $60,000 29 (30.9 %) -
No answer 5 (5.3 %) -
Years since diagnosis:
< 10 years 53 (56.4 %) -
10–19 years 31 (33 %) -
≥ 20 years 10 (10.6 %) -
Comorbidities (0–15) 1.78 ± 0.15 0 to 7
Cancer 54 (57.44 %) -
Heart disease 28 (29.7 %) -
OA 25 (26.5 %) -
PCS (0-52) 20.1 ± 13.2 0 to 51 0.95
PROMIS Anxiety (T-score) 57.9 ± 7.9 37.1 to 83.1 0.93
PROMIS Depression (T-score) 57.5 ± 8.4 37.1 to 81.1 0.93
TSK (0-68) 35.9 ± 7.9 18 to 58 0.84
Abbreviations: SD standard deviation, BMI body mass index, OA osteoarthritis,
PCS Pain Catastrophizing Scale, PROMIS National Institutes of Health Patient
Reported Outcome Measurement Information System, TSK Tampa Scale of
Kinesiophobia, T-score (mean of 50 with SD of 10)
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related to the parent study, including subject inclusion
and exclusion criteria, measures used in this analysis, and
their justification for use in the study have been reported
previously [29].
Subjects
Following approval by the Institutional Review Boards at
both study sites, 94 women with fibromyalgia were re-
cruited from the regions surrounding the University of
Iowa Hospitals and Clinics and Vanderbilt University.
Inclusion criteria for the individuals with fibromyalgia
included: (1) females ages 18–70 years, (2) diagnosis of
fibromyalgia confirmed with ACR 1990 criteria with 11
of 18 tender points (TeP) with TeP examination, (3) pain
greater than or equal to 4/10 at time of telephone screen,
(4) history of cervical or lumbar pain, (5) current stable
treatment regimen for the last 4 weeks and projected
stable treatment regimen for the next 2 months, and (6)
ability to speak English. Subjects were excluded if they
had: (1) current or history of cardiovascular, pulmonary,
neurological, endocrine, or renal disease that would pre-
clude involvement in the study, (2) TENS use in the last
5 years, (3) pacemaker, (4) uncontrolled blood pressure
or diabetes, (5) neuropathic pain condition, (6) systemic
autoimmune disorder, (7) cervical or lumbar fusion or
metal implants, (8) severe skin allergy to adhesive, (9) al-
lergy to nickel, (10) pain less than 4, (11) pregnancy, (12)
epilepsy, (13) change in treatment program (pharmaco-
logical or nonpharmacological) within the last month or
planned for the next 2 months, (14) unstable medical or
psychiatric condition which in the opinion of the investi-
gator could compromise the subject’s welfare or confound
the study results, (15) chest pain with activity such as
walking or climbing stairs, and (16) ambulation with as-
sistive device, e.g., cane or walker.
Pain intensity measure
An 11-point Numeric Rating Scale (NRS) was used for
measurement of pain intensity at rest and with movement
(during 6MWT). The pain NRS scale was vertical with
anchors at the bottom, “no pain,” and top, “worst pain
imaginable”. Pain NRS has adequate test-retest reliability
(r = 0.63) [30].To examine the impact of movement on
pain we calculated each individual’s ‘pain change’ score as
movement minus resting pain.
Fatigue intensity measure
An 11-point (0–to 10) NRS was used to measure per-
ceived fatigue intensity at rest and with movement (during
a 6MWT, see below). The fatigue NRS scale was vertical
with anchors at the bottom, “no fatigue,” and top, “worst
fatigue imaginable”. The psychometric properties of this
fatigue NRS have not been determined. However, similar
NRS scales for pain have established reliability and validity
as discussed above [31]. To examine the impact of move-
ment on fatigue intensity we calculated each individual’s
‘fatigue change’ score as movement fatigue intensity minus
resting fatigue intensity.
Self-report function measures
Fibromyalgia Impact Questionnaire Revised (FIQR)
The FIQR is a 21-item standard measure used as an index
of fibromyalgia disease activity and impact over the past
7 days [18]. Subjects are asked to indicate the degree to
which fibromyalgia has impacted multiple domains. The
three domains of the FIQR include function (nine items),
symptoms (ten items) and overall impact (two items).
For this study, only the function domain was used as a
measure of disease-specific perceived function. The nine-
function questions ask the subject to score the level of
difficulty (0–10 scale from “no difficulty” to “very difficult”)
with the following tasks: brush or comb your hair; walk
continuously for 20 minutes; prepare a homemade meal;
vacuum, scrub or sweep floors; lift and carry a bag full of
groceries; climb one flight of stairs; change bed sheets; sit
in a chair for 45 minutes; and go shopping for groceries.
Each of the nine items is scored 0–10, summed, and then
divided by three for a possible score of 0–30, where a
higher score indicates greater perceived functional diffi-
culty. The FIQR-Function domain demonstrates conver-
gent validity when compared to SF-36 physical function
(SF-36-PF) subscale (r = 0.80, p < 0.001) [18].
Multidimensional Assessment of Fatigue (MAF)
The MAF is a 16-item self-report measure of fatigue used
in chronic illness that can be subdivided into four dimen-
sions: severity, distress, timing (over the past week, when
Table 2 Summary of pain, fatigue, and function scores (N = 94)
Variable Mean ± SD Range Cronbach's α
Pain rest (0–10) 6.0 ± 1.6 2 to 10 0.53
Pain movement (0–10) 6.4 ± 1.9 2 to 10
Pain change score 0.3 ± 1.7 (-5.5) to 6
Fatigue rest (0–10) 6.5 ± 2.0 2 to 10 0.54
Fatigue movement (0–10) 5.6 ± 2.5 0 to 10
Fatigue change score (-0.9) ± 2.4 (-8) to 5
FIQR-Function (0–30) 15.1 ± 5.8 1.3 to 28.3 0.89
MAF-ADL (0–10) 5.8 ± 1.8 2.1 to 10 0.86
SF-36-PF (T-score) 33.4 ± 7.5 19.3 to 49.9 0.84
6MWT (feet) 1313.6 ± 323.5 100 to 2000 -0.042
5TSTS (seconds) 13.4 ± 6.6 6 to 51.5
Abbreviations: SD standard deviation, FIQR-Function Fibromyalgia Impact
Questionnaire Revised - Function Subscale, MAF-ADL Multidimensional
Assessment of Fatigue - Activities of Daily Living, SF-36-PF Short-Form Health
Survey Physical Function Subscale, 6MWT 6-Minute Walk Test, 5TSTS Five Time
Sit to Stand, T-score (mean of 50 with SD of 10), and change scores: movement –
resting scores
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it occurred and any changes), and impact on various activ-
ities of daily living (ADL) (household chores, cooking,
bathing, dressing, working, socializing, sexual activity, leis-
ure and recreation, shopping, walking, and exercising).
We used the ADL subscale of the MAF as a fatigue-
specific measure of self-reported function, where a higher
score indicates greater perceived functional difficulty
with ADLs. Psychometric properties for the ADL sub-
scale have not been established. The MAF has been
shown to have internal consistency r = 0.93; and con-
vergent validity with a fatigue Visual Analogue Scale
(VAS) r = 0.80, p < 0.05 [32].
SF-36
The SF-36 is a commonly used survey of self-reported
patient health. It has 36 questions with eight sections:
vitality, physical functioning, bodily pain, general health
perceptions, physical role functioning, emotional role
functioning, social role functioning and mental health
[33]. We used the physical functioning subscale as a
measure of global self-reported function (not disease-
or symptom-specific). It consists of ten items, inquiring
if health limits physical activity, basic mobility and basic
activities of daily living on a 4-point scale: yes, limited a
lot; yes, limited a little; and no, not limited at all. The
SF-36 raw data is rescaled to a T-score with a mean of
50 and a standard deviation (SD) of 10 with higher
scores demonstrating better health. The physical func-
tion subscale raw score is also converted to a T-score
with a mean of 50 and a SD of 10 (lower scores indicate
worse function). The SF-36-PF Subscale has internal
consistency of 0.62 to 0.96 and test-retest reliability of
0.42 to 0.90 [33].
Physical performance measures
Six-Minute Walk Test (6MWT)
Subjects completed the 6MWT using a 100-foot lap with
a turn at the 50-foot mark. Pain and fatigue ratings (NRS)
were completed at the 5-minute mark The 6MWT is a
standard function test that measures the maximum dis-
tance (feet) a person can walk as fast as is comfortable in
6 minutes. NRS pain and fatigue intensities were rated
near the end of the task for ratings of movement pain
and movement fatigue, respectively. The 6MWT is a
submaximal test of aerobic capacity with indications for
endurance [34]. The 6MWT has excellent test-retest reli-
ability (intraclass correlation coefficient (ICC) = 0.95–0.97)
and construct validity (r = 0.63–0.79) [34].
Five Time Sit to Stand Test (5TSTS)
The 5TSTS is a test of lower body strength. Subjects
completed the test with five repetitions of sit to stand
transitions, completed as quickly as possible. The time to
complete five repetitions was recorded. Pain and fatigue
ratings (NRS) were completed at the end of the test. The
time it takes to complete five repetitions of sit to stand,
completed as quickly as possible, is recorded. The 5TSTS
has adequate test-retest reliability (ICC > 0.83) [35, 36].
Psychological measures
Pain catastrophizing, fear of movement, anxiety and de-
pression are psychological factors that can influence
pain, fatigue, and function [37]. Thus, we assessed and
adjusted our analyses for the following psychological
variables:
Pain Catastrophizing Scale (PCS)
The PCS is a 13-item questionnaire regarding feelings
and thoughts related to the experience of pain. The PCS
has demonstrated internal consistency with Cronbach's
alpha = 0.95 and criterion related validity with Cronbach's
alpha = 0.42 [38].
Fear of movement (Tampa Scale of Kinesiophobia, TSK)
The TSK is a 17-item measure of fear of movement or
re-injury that is used in patients with chronic pain consid-
ering multiple scenarios (e.g., physical and work activity).
Test-retest reliability is good with r = 0.78 and good internal
consistency with Cronbach's alpha equal to 0.76 [39, 40].
PROMIS Short Form 8a Anxiety and 8b Depression
The NIH Patient Reported Outcome Measurement In-
formation System (PROMIS) Short Forms assess universal
rather than disease-specific questions regarding anxiety
(eight items) and depression (eight items) in the last 7 days.
Each scale consists of eight questions scored from 1 to 5
for a total raw score ranging from 8 to 40. The raw scores
are converted to separate T-scores for comparison of the
anxiety and depression scales. The T-score rescales each
raw score into a standardized score based on a standard
population with a mean of 50 and a standard deviation
(SD) of 10 [41]. A score higher than 50 represents greater
anxiety or depression and a score lower than 50 represent
less anxiety or depression. The Anxiety scale measures
self-reported fear, anxious misery, hyperarousal and som-
atic symptoms related to arousal [41]. The Depression
scale measures negative mood, views of self, social cogni-
tion and decreased positive affect and engagement [41].
Psychometric properties for the eight- item Short Form
have not been established. However the four-item Short
Forms for anxiety and depression demonstrate good in-
ternal consistency with Cronbach's alpha of 0.89 ± 1.24
standard error of measure (SEM) and 0.93 ± 1.08 (SEM),
respectively [42].
Data analysis
Normality was assessed utilizing Kolmogorov-Smirnov test.
Descriptive statistics (mean, standard deviation) were
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calculated for clinical characteristics and outcome vari-
ables. The relationships between individual variables were
assessed using Pearson’s correlation coefficients and corre-
lations r < 0.70 was utilized for inclusion in the analysis. In
particular, the associations between the control variables,
the predictor variables and the outcome variables were
assessed separately. Internal consistency of variables were
calculated and represented with Cronbach’s alpha in
Tables 1 and 2.
The relationships between pain and fatigue with our
primary outcome variables of perceived function (FIQR-
Function, MAF-ADL and SF-36-PF) and secondary out-
come variables of physical performance (6MWT, 5TSTS)
were explored using hierarchical linear regression ana-
lyses (30 calculations were completed). We first included
demographic (age and BMI) and psychological variables
(pain catastrophizing, fear of movement, anxiety, depres-
sion) in our base regression models to understand the
contributions of these control variables in predicting our
outcome variables (step 1). Then separately, either pain
(resting pain, movement pain, or pain change, step 2A)
or fatigue (resting fatigue, movement fatigue, or fatigue
change, step 2B) variables were added to the base models
to examine how either pain or fatigue alone would im-
prove the fit of the regression models in predicting per-
ceived function or physical performance over the control
variables. These are referred to as the single-predictor
models, serving as intermediate steps in our hierarchical
regression. Lastly, both pain and fatigue (resting, move-
ment, or change) variables were included in the final step
(step 3) for each of the five outcome variables. This
allowed us to determine the degree to which accounting
for both pain and fatigue improved the regression model
fits beyond the single-predictor models which only in-
cluded either pain or fatigue in isolation. For each step,
adjusted R2 values were calculated, reflecting the propor-
tion of variance in the outcome variable explained by the
model, adjusted for the number of predictors included in
the model. The significance of the change in R2 (ΔR2) be-
tween successive steps was assessed to determine whether
the addition of pain or fatigue variables resulted in a sig-
nificant improvement in predicting each outcome variable.
To determine if the combination of pain and fatigue
proved to be significantly better at predicting the out-
comes than either pain or fatigue alone, the step 3 models
were compared to the better of the two single-predictor
(step 2A or 2B) models. To address our secondary aim,
comparing resting, movement, and change scores for pain
and fatigue, the models’ R2 values using each form of as-
sessment at each step in the hierarchical regression were
compared. Because of the potential outlier BMIs in the
study we repeated the analysis with the removal of the sin-
gle highest BMI (70.19), and removal of the highest three
BMI values (52.61, 70.19, 54.24). The regression models
with and without these potential outliers did not signifi-
cantly change. Thus, we report the data for the complete
set only for brevity. The Statistical Package for the Social
Sciences (IBM SPSS v.21, IBM Corp., Armonk, NY, USA)
was used for all statistical analyses; significance was set at
p ≤ 0.05 and p values are provided for each test.
Results
Clinical characteristics
Ninety-four women with fibromyalgia with an average
age of 49.2 years (range 20–67) and BMI of 33.8 kg/m2
(range 19.1–70.2) participated in the study (Table 1). The
majority of the subject sample was Caucasian (93.6 %),
had an income less than $60,000 per year (63.8 %) and
attained an education level of some college or more
(70.2 %). Approximately half were married or cohabitating
(48.9 %) and half were single, widowed, or divorced
(48.9 %). There was a wide range of scores on the psycho-
logical factors from within normal range to the extreme
range for pain catastrophizing, fear of movement, anxiety
and depression. Comorbidities were collected and the
three comorbidities that occurred in greater than 25 % of
the sample were included in Table 1.
Resting pain intensity in this sample averaged 6.0 ± 1.6
(mean ± SD), while movement pain intensity averaged
6.4 ± 1.9 (mean ± SD) (Table 2). The change in pain in-
tensity from resting to during movement averaged 0.3 ±
1.7, with a wide range of responses from a decrease in
intensity of up to 5.5/10 to an increase of up to 6/10.
Similarly, resting fatigue intensity averaged 6.5 ± 2.0 and
movement fatigue intensity averaged 5.6 ± 2.51. The
change in fatigue intensity from resting to during move-
ment ranged from a decrease of 8 to an increase of 5,
with an average decrease in fatigue intensity rating after
performing the 6MWT (-0.9 ± 2.4). Thus, some people
showed a reduction in pain and fatigue intensity with
movement while others showed increases.
Fibromyalgia subjects showed significant impairments
in perceived function and physical performance (Table 2).
The FIQR-Function scale averaged 15.1 ± 5.8 (on a 0 to
30 scale), the MAF-ADL subscale averaged 5.8 ± 1.8 (0–10),
and the SF-36-PF averaged 33.4 ± 7.5 (T-score with 50 aver-
age). For physical performance tasks, subjects walked
1313.6 ± 323.5 feet on the 6MWT (1876 feet is normal in
60- to 69-year-old females [34]) and took 13.4 ± 6.6 seconds
to complete the 5TSTS (11.4 seconds normal for age
60–69 years [34]).
Correlation analysis
The psychological traits were significantly correlated with
the control variables (Table 3). Age and BMI were not cor-
related with any of the other control variables. Anxiety,
depression, and pain catastrophizing were strongly corre-
lated with each other (r = 0.60 – 0.66). Fear of movement
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moderately correlated with pain catastrophizing (r = 0.47)
and anxiety (r = 0.39) and weakly correlated with depres-
sion (r = 0.28).
Resting and movement pain and fatigue were moder-
ately correlated with each other (Table 4). The change
scores were consistently positively correlated with move-
ment assessments, and negatively correlated with resting
assessments (the higher the resting score, the lower the
change with movement). Movement pain and fatigue from
the 6MWT was moderately correlated with the movement
pain and fatigue from the 5TSTS. Since 6MWT was
performed first and is a common test in a variety of
populations, movement pain and fatigue from the 6MWT
was used to represent movement pain and fatigue in the
analysis.
Perceived function measures (FIQR-Function, MAF-ADLs
and SF-36-PF) and physical performance measures (6MWT,
5TSTS) were all weakly (r = 0.30) to moderately (r = 0.66)
correlated (Table 5). The highest correlations were between
the three perceived function measures, FIQR-Function,
MAF-ADL, and SF-36-PF, with SF-36-PF score inversely
related to the FIQR-Function and MAF-ADL scores due
to the reverse scaling of that instrument. Similarly, the
physical performance assessments (6MWT and 5TSTS)
were weakly to moderately correlated with the three
perceived function assessments (Table 5).
Perceived function
The results of the hierarchical linear regression models
for the three perceived function measures are provided
in Table 6. The control variables in step 1, i.e., age, BMI,
and psychological factors, significantly predicted from
11 % to 22 % of the variance in perceived function
(Table 6). The addition of either pain or fatigue (steps
2A or 2B) provided a significant improvement over the
base model for the majority of the three perceived func-
tion outcomes. Change in pain (step 2A) was not better
than the control variables alone for FIQR-Function (p =
0.12). The addition of resting pain to the control variables
did not help explain the MAF-ADL (p = 0.11). For the
models including a fatigue predictor (step 2B), the change
score never improved the model predictions of perceived
function over the control variables (p = 0.23 – 0.33).
Supporting our initial hypothesis, including both move-
ment pain and fatigue variables in the regression models
(step 3) consistently resulted in significantly better pre-
dictions of perceived function based on the FIQR and
MAF-ADL, indicating both pain and fatigue uniquely
contribute to these outcomes than either one alone. For
the MAF-ADL, the addition of resting pain (step 3) was
not better than the model relying on resting fatigue
alone (step 2B). The perceived function assessed by the
SF-36 was approximately equally well predicted by either
pain or fatigue alone, but no significant improvement was
seen by including both pain and fatigue in the model.
Overall, self-reported movement pain and fatigue inten-
sities explained a higher proportion of the variance
observed in all three perceived function assessments
(FIQR-Function, MAF-ADL, and SF-36-PF) than self-
reported resting pain and fatigue intensities (Table 6).
This was most notable for the resting pain scores as
resting fatigue typically explained a greater proportion
of perceived function than resting pain. However, move-
ment pain intensity was often superior to movement fa-
tigue intensity when they were considered in isolation
(see Table 6). The change scores for pain or fatigue in-
tensities were not strongly associated with perceived
function. Only two of the nine possible models including
a change score provided significantly more predictive
value than the lower level corresponding model: change in
pain provided significantly more information than the
control variables alone for MAF-ADL and SF-36-PF.
Overall, movement pain and movement fatigue intensities
together explained from 34 % to 42 % of the variance in
perceived function, after controlling for age, BMI, pain
Table 3 Pearson correlation coefficients between control
variables
Age TSK PCS Anxiety Depression
BMI (kg/m2) 0.157 -0.067 -0.16 -0.13 -0.085
Age (years) -0.124 -0.088 -0.08 0.003





Abbreviations: BMI body mass index, TSK Tampa Scale of Kinesiophobia, PCS
Pain Catastrophizing Scale
**p ≤ 0.01 level, *p ≤ 0.05 level
Table 4 Pearson correlation coefficients between pain and fatigue predictor variables
Pain movement Pain change Fatigue rest Fatigue movement Fatigue change
Pain rest 0.505** -0.363** 0.589** 0.186 -0.312**
Pain movement 0.621** 0.512** 0.450** -0.002
Pain change 0.019 0.313** 0.281**
Fatigue rest 0.434** -0.367**
Fatigue movement 0.679**
**p ≤ 0.01 level, *p ≤ 0.05 level
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catastrophizing, fear of movement, anxiety and depres-
sion, an increase of 19 to 29 % of the variance explained
compared to the control variables alone.
Physical performance
The results of the hierarchical linear regression models
for the two physical performance measures are provided
in Table 7. The control variables in step 1, i.e., age, BMI,
and psychological factors, predicted 31 % of the variance
in the 6MWT, but only 5 % of the 5TSTS. The addition
of movement pain (step 2A) provided a significant im-
provement over the base model for either 6MWT or
5TSTS. Resting pain and pain change did not significantly
account for variance in 6MWT or 5TSTS. Both resting
and movement fatigue (step 2B) also provided a significant
improvement in predicting physical performance over the
control variables alone (step 1), but movement fatigue pro-
duced a larger improvement than resting fatigue. Change
in pain or fatigue scores did not significantly improve the
models, except for predicting the 5TSTS, which was
similar to the resting fatigue model. Including both
pain and fatigue in the regression models (step 3) did
not result in better predictions of physical performance
compared to either fatigue or pain alone (steps 2A or 2B),
contrary to our initial hypothesis.
Consistent with perceived function models, self-reported
movement pain or fatigue intensities were consistently
better than resting pain or fatigue intensities. Movement
pain and movement fatigue intensities explained 40 % and
38 % of the variance in the 6MWT, respectively. Thus, the
42 % of the variance explained by the model including
both movement pain and fatigue intensities was not sig-
nificantly better than the individual scores. For the 5TSTS,
movement fatigue intensity was a better predictor of
performance than movement pain intensity (20 % vs 8 %
variance explained by each respective model), and the in-
clusion of both did not significantly improve the variance
explained (20 %).
Overall, movement pain and movement fatigue inten-
sities together or in isolation were able to explain from
20 % to 42 % of the variance in physical performance,
after controlling for age, BMI, pain catastrophizing, fear
of movement, anxiety and depression. This represents
an increase of 11 to 15 % of the variance explained com-
pared to the control variables alone.
Discussion
The current study shows that both pain and fatigue in-
tensities are significant contributors to perceived func-
tion and physical performance. Using different perceived
function measures and physical performance measures
Table 5 Pearson correlation coefficients between function
outcome variables
MAF-ADL SF-36-PF 6MWT 5TSTS
FIQR-Function 0.617** -0.655** -0.405** 0.426**
MAF-ADL -0.533** -0.313** 0.301**
SF-36-PF 0.457** -0.314**
6MWT -0.534**
Abbreviations: MAF-ADL Multidimensional Assessment of Fatigue - Activities of
Daily Living, SF-36-PF Short-Form Health Survey Physical Function Subscale,
6MWT 6-Minute Walk Test, 5TSTS Five Time Sit to Stand, FIQR-Function Fibromyalgia
Impact Questionnaire Revised - Function Subscale
**p ≤ 0.01 level, *p ≤ 0.05 level
Table 6 Hierarchical linear regression models for pain, fatigue, and pain and fatigue predicting the perceived function outcome
variables, FIQR-Function, MAF-ADL, and SF-36-PF, controlling for age, BMI, pain catastrophizing, fear of movement, anxiety, and
depression
FIQR-Function MAF-ADL SF36-PF












Step 1 Control variables 0.13** 0.22** 0.11*
Step 2A: pain Resting 0.29** 0.16 <0.001 0.23** 0.01 0.11 0.17** 0.06 0.01
Movement 0.37** 0.26 <0.001 0.32** 0.1 <0.001 0.33** 0.22 <0.001
Change 0.15** 0.02 0.12 0.26** 0.04 0.02 0.18** 0.07 0.007
Step 2B: fatigue Resting 0.29** 0.16 <0.001 0.30** 0.08 0.002 0.19** 0.08 0.004
Movement 0.31** 0.18 <0.001 0.39** 0.17 <0.001 0.22** 0.03 0.001
Change 0.13** 0 0.23 0.25** 0.03 0.33 0.12* 0.01 0.27
Step 3: pain and fatigue Resting 0.32** 0.11 0.03 0.29** 0.03 0.76 0.19** 0.08 0.28
Movement 0.42** 0.29 0.006 0.41** 0.19 ≤0.001 0.34** 0.23 0.1
Change 0.14** 0.01 0.49 0.27** 0.05 0.15 0.17** 0.06 0.83
Control variables: age, body mass index (BMI), pain catastrophizing (PCS), fear of movement (TSK), anxiety (PROMIS Anxiety), and depression (PROMIS Depression).
Resting, movement, and change scores entered into separate regression models for pain (step 2A), fatigue (step 2B), and pain and fatigue together (step 3).
Abbreviations: FIQR-Function Fibromyalgia Impact Questionnaire Revised - Function Subscale, MAF-ADL Multidimensional - Assessment of Fatigue Activities of Daily
Living, SF-36-PF Short-Form Health Survey Physical Function
R2 significance level: **p ≤ 0.01 level; *p ≤ 0.05 level
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we show different contributions of pain and fatigue
supporting that they are unique constructs affecting
perceived function and physical performance Interest-
ingly, in the current study there was a wide variation in
the pain and fatigue response to movement with some
showing increases and others no change or a decrease,
suggesting a heterogeneous response to movement. In
our models, pain and fatigue, along with demographic
and psychological variables, explain up to 43 % of the
variance observed in perceived function and up to 41 %
of the variance observed in physical performance.
Perceived function
Perceived function has previously been measured in
women with fibromyalgia with a variety of self-report
measures [43, 44]. In agreement with the current study,
Wolfe et al. found that the primary determinants of glo-
bal severity and disease impact were pain, fatigue and
function in individuals with fibromyalgia [13] In addition
to the FIQR and SF-36, we also examined the MAF-ADL
as an additional measure of perceived function. Each tool
provides a slight variation on perceived fatigue. The FIQR
is a disease-specific measure of perceived function. The
SF-36 is used across a wide range of patient populations
as well as healthy control populations [44] making it a
general measure of perceived function. The MAF-ADL
provides an alternate assessment of perceived function
with a greater emphasis on the impact of fatigue. Our
findings extend the results from prior studies by examin-
ing the unique and distinct influences of pain and fatigue
on evaluating perceived function using multiple related,
yet unique, measures.
Both the FIQR-Function and MAF-ADL were better
represented by the inclusion of both pain and fatigue in-
tensities in the model. The inclusion of pain and fatigue
did not better explain the SF-36-PF. However, when pain
or fatigue were considered in isolation, the FIQR-Function
and SF-36-PF were equally well represented by either pain
or fatigue, suggesting similar degrees of influence on these
measures of perceived function. Conversely, for the
MAF-ADL, fatigue was a better predictor than pain alone,
consistent with its development as a tool to assess the
impact of fatigue. Despite this, pain provided additional
information in predicting the MAF-ADL, beyond fatigue
alone. Thus, pain and fatigue are related to all three as-
sessments of perceived function, particularly movement
pain and movement fatigue.
Psychological and demographic variables also contrib-
uted to perceived function. We found 11–22 % of the
variance in perceived function was explained by a com-
bination of age, BMI, and psychological traits. Pain cata-
strophizing was associated with duration of fibromyalgia
diagnosis (r = 0.27–0.73, p < 0.05) [45], and predicted
perception of pain better than age or education [46].
Prior studies also show that anxiety and depression con-
tribute to decreased perceived function and increased
disease impact [47, 48]. The relationship between fear of
movement and perceived function in individuals with
fibromyalgia had not been previously studied. The asso-
ciations observed between these variables in our cohort
support that anxiety, depression, catastrophizing and fear
are significantly related, and collectively influence perceived
function in women with fibromyalgia.
Physical performance
Few studies have examined physical performance in indi-
viduals with fibromyalgia, and fewer still have examined
factors associated with physical performance. We exam-
ined, for the first time, the association of pain and fatigue
with two performance measures, the 6MWT and 5TSTS
Table 7 Hierarchical linear regression predicting the function outcome variables, 6-Minute Walk Test (6MWT) and Five Time Sit To
Stand (5TSTS), controlling for age, BMI, pain catastrophizing, fear of movement, anxiety, and depression
6MWT 5TSTS
Adj. R2 Change (Δ) in R2 p value R2 change Adj. R2 Change (Δ) in R2 p value R2 change
Step 1 Control variables 0.31** 0.05
Step 2A: pain only Resting 0.35** 0.04 0.26 0.05 0 0.34
Movement 0.40** 0.09 0.001 0.08* 0.03 0.05
Change 0.33** 0.02 0.1 0.06 0.06 0.25
Step 2B: fatigue Resting 0.35** 0.04 0.01 0.10* 0.05 0.03
Movement 0.38** 0.07 0.001 0.20** 0.15 <0.001
Change 0.32** 0.01 0.17 0.10* 0.05 0.02
Step 3: pain and fatigue Resting 0.35** 0.02 0.35 0.09* 0.04 0.62
Movement 0.42** 0.11 0.17 0.20** 0.15 0.71
Change 0.33** 0.02 0.39 0.10* 0.05 0.71
Control variables: age, body mass index (BMI), pain catastrophizing (PCS), fear of movement (TSK), anxiety (PROMIS Anxiety), and depression (PROMIS Depression)
R2 significance level: **p ≤ 0.01 level; *p ≤ 0.05 level
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and show movement pain is associated with performance
on 6MWT while resting and movement fatigue is asso-
ciated with performance on the 5TSTS. In agreement
with our study, a small study (n = 18) showed higher
self-reported pain on the FIQ correlated with reduced
walking distance in the 6MWT [49]. Previous studies
suggest that the 6MWT is a measure of endurance and
the 5TSTS is a measure of strength [34, 50, 51] and are
therefore thought to be different measures of perform-
ance. Our data confirm these measures are distinct and
suggest pain has more influence on endurance whereas
fatigue is more closely associated with strength. How-
ever, fatigue and endurance are inherently related con-
structs [13], thus this finding is somewhat unexpected.
We cannot rule out that this difference may be a result
of the relatively small variance explained in the 5TSTS
overall (20 %) relative to the 6MWT (42 %). The con-
trol variables, including age, BMI, and psychological
traits, explained only 5 % of the variance in the 5TSTS,
whereas 31 % of the variance in the 6MWT was ex-
plained by the control variables. These data support our
proposal that physical performance measures are uniquely
different from perceived function and thus provide a use-
ful additional outcome measure to examine function in
people with fibromyalgia.
Fibromyalgia and fatigue
Few studies have focused on fatigue in people with fibro-
myalgia despite the fact that the majority of people with
fibromyalgia report fatigue in a similar frequency to pain
[52, 53]. Indeed we show that fatigue is a common prob-
lem in this sample, averaging 6.5 on a 10-point scale. Fur-
ther fatigue played a significant role in perceived function
and physical performance. Our results support the inclu-
sion of movement fatigue measures, in addition to move-
ment pain measures, in future studies involving individuals
with fibromyalgia since fatigue also influences physical
performance and perceived function.
Fibromyalgia and pain
A number of studies have examined predictors of pain
in individuals with fibromyalgia. These studies in general
show that psychological factors, quantitative sensory tests,
and clinical characteristics (age, BMI) contribute to the
severity of pain [1, 54, 55]. Specifically, in people with
fibromyalgia (n = 74), anxiety was most closely associ-
ated with the sensory dimension of pain, helplessness
was most closely associated with the affective dimension
of pain, and fear of pain was closely associated with pain
intensity [47]. Further, chronic widespread pain was pre-
dicted by the number of body pain areas, negative affect,
heat, temporal summation of pain and ratings of “after
sensations” [1, 54]. Greater physical pain was reported by
women with fibromyalgia who were older, less educated,
more depressed, and had higher BMI and those with
osteoarthritis (n = 238) [55]. Interestingly, a combination of
tender point counts, negative affect and wind-up accounted
for pain after sensations contributing up to 27 % [1, 54].
Thus, multiple factors impact pain intensity experienced
with fibromyalgia including the number of body pain areas,
psychological constructs, and response to peripherally ap-
plied stimuli. The current study, on the other hand, showed
pain severity contributes to perceived function and physical
performance.
Limitations
While our intent was to assess perceived function and
physical performance, we recognize the physical per-
formance measures assessed (6MWT, 5TSTS) may not
fully represent an individual’s function at home, work or
in social situations. These assessments are commonly
used to identify function in research and clinical practice
settings using a standardized protocol, but may differ
from an individual’s daily function. Another limitation in
our study is the association between pain and fatigue
that may limit the ability of regression models to fully
assess their relative importance in predicting function.
However, the use of hierarchical models allowed us to
examine the contribution of each, limiting the influence
of colinearity on our conclusions. Another limitation is
the fact that we had a number of exclusion criteria, in-
cluding male sex, which may limit some generalizability.
In our sample, subjects had an average of 1.78 of 15 co-
morbidities with a range of 0 to 7. Finally, our analysis
did not include all possible relevant predictors to per-
ceived function and physical performance; the amount
of variance explained suggests other factors also contrib-
ute to these outcomes. Future studies would benefit
from the inclusion of sleep, physical activity levels and
self-efficacy as these factors have been shown to contrib-
ute to fatigue and pain in fibromyalgia [56, 57], and thus
could contribute to physical performance and perceived
function.
Conclusions
The impact of pain and fatigue intensities is an import-
ant consideration in the assessment and treatment of in-
dividuals with fibromyalgia in a clinical setting. While
these two constructs are clearly related, our findings in-
dicate that pain and fatigue each have independent con-
tributions to perceived function and physical performance.
Further, assessment of pain and fatigue with movement,
when compared to rest, shows greater associations with
function. Thus, these findings suggest it would be import-
ant to assess both pain and fatigue intensities during
clinical and functional activities and the timing of these
assessments (before and during activities) in the clinic
and at home may be important. Clinically, pain and
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fatigue may adversely impact patient performance, par-
ticipation and follow through at home, work or social
situations. Future studies should examine if interventions
that improve pain or fatigue can also improve perceived
function and physical performance.
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